John Lubniewski

Apr 16, 2018

John Lubniewski has been promoted by HTG Molecular Diagnostics to president and chief operating officer. Lubniewski has been the company's chief business officer for the past seven years. He joined HTG from Ventana, now part of Roche, where he held several senior leadership roles, and was responsible for marketing and global accountability for all assay products. Prior to joining Ventana, he was with Corning.

More Like This

Sep 14, 2018

Marco Casarin

Oncimmune has appointed Marco Casarin as General Manager, Oncimmune USA. Casarin previously held a position at Thermo Fisher Scientific. In addition, Casarin has held roles as senior commercial, marketing, and operating roles at Roche Diagnostics and Vela Diagnostics. 

Sep 12, 2018

Bob Petrou

Bob Petrou has been named interim CFO and interim principal financial officer of NantHealth, replacing Paul Holt, whose resignation was effective Sept. 11. He will earn about $36,000 per month under a consulting agreement with the company, NantHealth disclosed in a regulatory filing. Petrou most recently was head of finance for the mobility solutions division of smartphone maker BlackBerry. 

Sep 11, 2018

Christian Marcazzo

The IDBS informatics division of Danaher has hired Christian Marcazzo as vice president and general manager. Marcazzo comes to UK-based IDBS from PerkinElmer Informatics, where he had been VP for analytics and search. In his new role, Marcazzo will be responsible for all profit and loss functions, including developing and executing a business strategy, evaluating growth opportunities, and hiring sales and professional services personnel. Danaher bought IDBS in October 2017.

Sep 11, 2018

Allan Brown, David Matthews

QuantuMDx appointed Allan Brown as chief operating officer and David Matthews as chief financial officer. Brown was previously COO and a board director at Genedrive where he oversaw the launch of the company's PCR-based platform, also called Genedrive, for diagnosing hepatitis C. He previously was at Qiagen and Tepnel Life Sciences. Matthews was previously CFO at Contextual Genomics and was part of the founding team at GenomeDx Biosciences. 

Sep 11, 2018

Kelly Gebo

Kelly Gebo has joined the All of Us Research Program at the National Institutes of Health as chief medical and scientific officer. She is a professor of medicine at Johns Hopkins University and an expert in HIV health services research and HIV clinical outcomes. Gebo holds an MD from Johns Hopkins University School of Medicine and a master's degree in public health from the Johns Hopkins Bloomberg School of Public Health.

Sep 11, 2018

Charles David Allis, Michael Grunstein

Charles David Allis and Michael Grunstein have been awarded the 2018 Albert Lasker Basic Medical Research award for their discoveries showing how gene expression is influenced by the chemical modification of histones. Allis is the Joy and Jack Fishman Professor at Rockefeller University, where he heads the Laboratory of Chromatin Biology and Epigenetics. Grunstein is professor emeritus in the Department of Biological Chemistry at the David Geffen School of Medicine at the University of California, Los Angeles.

Sep 11, 2018

Ave Wrigley, Robert Thong, Julian Coe

British bioinformatics firm Repositive has named three new senior executives. Ave Wrigley has joined as chief technology officer, Robert Thong has been hired as chief business officer, and Julian Coe is the new chief finance and operating officer. Thong and Coe each has leadership experience in genomics, life sciences, and digital health companies, while Wrigley comes from an IT background in the e-commerce, data-driven marketing, and multimedia content management sectors.

Sep 11, 2018

Chitra Nayak

Invitae's board of directors this week expanded the number of members on its board to six members and appointed Chitra Nayak as a member. Nayak most recently served as chief operating officer of the real estate technology company Comfy, which was acquired by Siemens in June. Prior to that, Nayak worked at Funding Circle, an online peer-to-peer lending marketplace, and the cloud computing company Salesforce.com. Nayak will stand for re-election on Invitae's board in 2021.
Sep 11, 2018

Katherine Atkinson

Epic Sciences has appointed Katherine Atkinson as its chief commercial officer, charging her with the development of the firm's global commercial strategy. Atkinson joins Epic with two decades of life science and healthcare experience. Most recently, she served as vice president of business development at Edico Genome, where she established a global channel network and managed strategic partnerships. Prior to Edico she worked for Illumina, overseeing numerous teams, including molecular biology/PCR sales, inside sales, Latin America, and most recently global channel partners. She has also held positions at Fisher Scientific, Thermo Fisher, and Beckman Coulter.

Sep 10, 2018

Jack Challis

Cancer diagnostics shop Lucence Diagnostics appointed Jack Challis its healthcare analytics director. He will be based in San Francisco and will organize Lucence's streams of genomics data, as well as drive collaborations with research institutes and healthcare providers in the US. Challis cofounded CliniCast, which was acquired by Elekta in 2015. 

Sep 10, 2018

Edwin Hendrick

Biocept has appointed Edwin Hendrick as Senior Vice President and Chief Commercial Officer. Hendrick brings 25 years of sales and commercial leadership experience in the healthcare industry, with senior level commercial and operational positions at a variety of diagnostic and healthcare service companies. 

In his most recent position at GenomeDx, Hendrick developed the company's commercial strategy and launched its commercial offering. Prior to GenomeDx he served as executive vice president of sales and marketing at Plus Diagnostics. He also served as an executive with US Labs and led sales and marketing for Ventana Medical Systems after beginning his career in sales for Abbott Laboratories.

Sep 10, 2018

James Mullen

Thermo Fisher Scientific's board has elected James Mullen as a director, effective Nov. 8. He was appointed to the board's strategy and financing committee, and his term expires at the 2019 annual meeting. Mullen was CEO of Patheon until that firm's acquisition by Thermo Fisher in August 2017. Prior to Patheon, he was CEO and president of Biogen. 

Sep 07, 2018

Nikko Khazana and Mark Mozley

NantHealth has hired Nikko Khazana as senior VP for strategy and business development and Mark Mozley as SVP for global sales. Khazana had previously served as SVP of sales at CompanionDx Reference Lab. Mozley previously led sales efforts for life sciences and global strategic accounts at Clarivate Analytics. 

Sep 06, 2018

Steven Kafka

Steven Kafka has joined the board of directors of ArcherDX. He serves as a venture partner at Third Rock Ventures, and was previously the president and chief operating officer of Foundation Medicine, which is now owned by Roche. Before that, he was the COO and CFO of Aileron Therapeutics and VP of finance at Infinity Pharmaceuticals.

Sep 06, 2018

Linda Baddour, Gary Hendrickson

Waters announced today that has appointed Linda Baddour and Gary Hendrickson as directors of the firm.

Baddour has served as executive VP and CFO at PRA Health Sciences since 2007. Prior to PRA, she served as CFO at Pharmaceutical Product Development. Beforhand,  she also served as treasurer and chief accounting officer at the firm.

Prior to Waters, Hendrickson served as Chairman of  Valspar between 2012 and 2017, and CEO since 2011. Prior to CEO, Hendrickson acted as COO, president of several business units, and corporate VP and President of the firm's Asia Pacific branch.

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.